Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Conditions

Hepatoblastoma | Stage I Childhood Hepatocellular Carcinoma | Stage II Childhood Hepatocellular Carcinoma | Stage III Childhood Hepatocellular Carcinoma | Stage IV Childhood Hepatocellular Carcinoma

What is the purpose of this trial?

This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs (cancer fighting medicines), and when necessary liver transplant are the main current treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best treatment. Treating patients according to the risk group they are in may help get rid of the cancer, keep it from coming back, and decrease the side effects of chemotherapy.



Participation Guidelines

Age:
N/A - 21 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Cancer Institute (NCI)
Dates:
September 2009
Last Updated:
November 21, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT00980460